AbbVie Inc. (NYSE:ABBV) Stock Has Consensus Target Price of $272.66 According to Analysts

Shares of AbbVie Inc. (NYSE:ABBV) have been assigned an average rating of “Moderate Buy” from the thirty brokerages that are covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a hold rating, twenty-two have given a buy rating and two have given a strong buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $272.39.

ABBV has been the subject of a number of recent analyst reports. Argus raised their price objective on shares of AbbVie from $250.00 to $270.00 in a research report on Tuesday, August 4th. HSBC increased their price objective on AbbVie from $300.00 to $315.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Piper Sandler boosted their target price on shares of AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a research report on Thursday, August 20th. BNP Paribas Exane upped their price target on shares of AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 11th. Finally, BMO Capital Markets increased their target price on shares of AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a report on Monday, July 13th.

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.06% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. State Street Corp boosted its position in AbbVie by 1.7% during the second quarter. State Street Corp now owns 82,596,748 shares of the company’s stock worth $20,784,646,000 after acquiring an additional 1,379,232 shares during the last quarter. Capital Research Global Investors boosted its stake in AbbVie by 0.7% in the 4th quarter. Capital Research Global Investors now owns 25,408,200 shares of the company’s stock worth $5,805,530,000 after buying an additional 177,370 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in AbbVie by 0.7% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock valued at $3,590,323,000 after buying an additional 106,091 shares during the period. Franklin Resources Inc. increased its stake in shares of AbbVie by 2.3% during the 4th quarter. Franklin Resources Inc. now owns 14,881,504 shares of the company’s stock valued at $3,400,274,000 after acquiring an additional 330,104 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in shares of AbbVie by 9.7% during the 4th quarter. Bank of New York Mellon Corp now owns 13,499,351 shares of the company’s stock worth $3,084,467,000 after acquiring an additional 1,197,432 shares during the period. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Stock Up 1.3%

Shares of ABBV stock opened at $263.27 on Tuesday. The stock’s 50-day moving average price is $257.87 and its 200 day moving average price is $234.59. The stock has a market capitalization of $465.14 billion, a PE ratio of 74.37, a price-to-earnings-growth ratio of 1.19 and a beta of 0.24. AbbVie has a 52-week low of $190.75 and a 52-week high of $269.39.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. AbbVie’s quarterly revenue was up 10.2% on a year-over-year basis. During the same period last year, the firm posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Analysts expect that AbbVie will post 14.05 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s dividend payout ratio (DPR) is presently 195.48%.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The FDA approved AbbVie’s new Parkinson’s disease pill, Juvmo, with a commercial launch targeted for October 2026. The product expands AbbVie’s neuroscience portfolio and could provide another source of growth beyond its immunology franchise. FDA approves AbbVie’s Juvmo for Parkinson’s Disease
• Positive Sentiment: Analysts’ consensus price target was reportedly raised 10.06% to MX$5,190.34, reinforcing bullish expectations. Separately, one analysis estimated that ABBV could be 41% undervalued following the Juvmo approval, although valuation models are inherently subjective. AbbVie consensus price target increased
• Positive Sentiment: New long-term data showed AbbVie’s RINVOQ continued to improve facial and total-body repigmentation in non-segmental vitiligo patients through week 76. The findings may strengthen RINVOQ’s commercial opportunity, though safety, reimbursement and competitive considerations remain important. AbbVie presents long-term RINVOQ data
• Neutral Sentiment: AbbVie will report third-quarter 2026 results before the market opens on October 30. The event gives investors a near-term catalyst to assess Skyrizi and Rinvoq growth, the post-Humira transition and management’s outlook. AbbVie third-quarter 2026 earnings conference call
• Neutral Sentiment: An update on an ongoing Greek clinical study is evaluating venetoclax in acute myeloid leukemia. The study remains an incremental pipeline development rather than a definitive efficacy or regulatory catalyst. AbbVie’s Venetoclax AML study update
• Negative Sentiment: AbbVie agreed to participate in a U.S. government pilot testing a new prescription-drug rebate system. While participation could improve relations with policymakers and potentially expand access, changes to rebates and pricing may create uncertainty around net drug prices and margins. AbbVie joins U.S. government pilot to test drug discount rebates
• Negative Sentiment: Despite strong recent performance, investors continue to weigh AbbVie’s elevated valuation, Humira revenue erosion and competition affecting its growth outlook. These risks could limit further upside even as newer products gain traction.

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.